The EDC is live today — see what ships now
All studies
NCT07489651From ClinicalTrials.govRecruiting

RE104 Safety and Efficacy Study in Generalized Anxiety Disorder

A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of RE104 for Injection in the Treatment of Generalized Anxiety Disorder

  • Generalized Anxiety Disorder

At a glance

Phase
Phase 2
Study type
Interventional
Sponsor
Reunion Neuroscience Inc
Enrolment target
160
Started
20 April 2026
Main results due
July 2027
Study sites
28
Registry updated
24 September 2026

Can you take part?

  • Ages 18 years to 74 years.
  • Open to any sex.
  • You need the condition being studied — healthy volunteers are not accepted.

These are the headline rules only. Every study has a longer list, and whether you are eligible is decided by the research team at the site — never by this page.

Read the full eligibility criteria
Inclusion Criteria:

* Has Generalized Anxiety Disorder as defined by DSM-5-TR
* If female is not pregnant or planning to become pregnant. If male is not planning to make a partner pregnant.
* Is willing and able to comply with the conditions and requirements of the study

Exclusion Criteria:

* Has a significant risk of suicide
* Has an active or medical history of bipolar disorder, schizophrenia, schizoaffective disorder, psychotic disorder and/or borderline personality disorder, or first-degree family history of psychosis or bipolar disorder
* Has other concurrent psychiatric disorders that is the primary disorder.
* Has other medically significant conditions rendering unsuitability for the study
* Has used or will need to use prohibited medications or therapies
* Has a known sensitivity or intolerance to study intervention or potential rescue medications

What this study is about

In the sponsor’s own words, from the registry.

The purpose of this study is to determine if treatment with a single and/or repeat dose of RE104 for Injection reduces anxiety symptoms in participants with Generalized Anxiety Disorder (GAD) as compared to placebo.

Study sites(28)

  • University of Alabama (UAB) Clinical Research Unit (CRU)

    Birmingham, Alabama, United States

    Recruiting

  • Lighthouse Psychiatry

    Gilbert, Arizona, United States

    Recruiting

  • Preferred Research Partners, Inc.

    Little Rock, Arkansas, United States

    Recruiting

  • Collaborative Neuroscience Research, LLC

    Garden Grove, California, United States

    Recruiting

  • Kadima Neuropsychiatry Institute

    La Jolla, California, United States

    Recruiting

  • Open Mind Therapeutics

    San Francisco, California, United States

    Recruiting

  • TRIP Clinic at Psychedelic Science Institute

    Santa Monica, California, United States

    Recruiting

  • Innovative Clinical Research, Inc.

    Lauderhill, Florida, United States

    Recruiting

  • University of South Florida

    Tampa, Florida, United States

    Recruiting

  • Atlanta Center for Medical Research

    Atlanta, Georgia, United States

    Recruiting

  • CenExel iResearch, LLC

    Decatur, Georgia, United States

    Recruiting

  • Evergreen Clinical Trials

    Norcross, Georgia, United States

    Recruiting

  • CenExel iResearch, LLC

    Savannah, Georgia, United States

    Recruiting

  • Uptown Research Institute

    Chicago, Illinois, United States

    Recruiting

  • Henry Ford Medical Center - Columbus

    Novi, Michigan, United States

    Recruiting

  • Midwest Research Group

    Saint Charles, Missouri, United States

    Recruiting

  • UNM Research Program Psychedelic Therapies

    Albuquerque, New Mexico, United States

    Recruiting

  • NYU-H+C Clinical and Translational Science Institute

    New York, New York, United States

    Recruiting

  • University of North Carolina at Chapel Hill

    Chapel Hill, North Carolina, United States

    Recruiting

  • Neuro-Behavioral Clinical Research, Inc.

    North Canton, Ohio, United States

    Recruiting

  • Summit Headlands LLC

    Portland, Oregon, United States

    Recruiting

  • University of Pennsylvania

    Philadelphia, Pennsylvania, United States

    Recruiting

  • Suburban Research Associates

    West Chester, Pennsylvania, United States

    Withdrawn

  • Austin Clinical Trial Partners

    Austin, Texas, United States

    Recruiting

  • BioBehavioral Research Austion

    Austin, Texas, United States

    Recruiting

  • Aim Trials, LLC

    Plano, Texas, United States

    Recruiting

  • Cedar Clinical Research

    Draper, Utah, United States

    Recruiting

  • Inner Space State Street

    Orem, Utah, United States

    Recruiting

Showing 28 of 28 sites. 27 of the 28 sites on this study are recruiting right now — a site can stop enrolling while the study as a whole is still open.

Source: ClinicalTrials.gov record NCT07489651. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.

Not the right study?

Answer three questions and see the studies recruiting near you, in plain language.

Find a study for me
RE104 Safety and Efficacy Study in Generalized Anxiety Disorder | Trialion